Predictive Oncology (NASDAQ: POAI)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.050 | ||||||
REV | 314.568K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Predictive Oncology (NASDAQ: POAI) through any online brokerage.
Other companies in Predictive Oncology’s space includes: Pulmonx (NASDAQ:LUNG), RxSight (NASDAQ:RXST), TELA Bio (NASDAQ:TELA), Chembio Diagnostics (NASDAQ:CEMI) and Meihua International (NASDAQ:MHUA).
The latest price target for Predictive Oncology (NASDAQ: POAI) was reported by HC Wainwright & Co. on Wednesday, June 30, 2021. The analyst firm set a price target for 5.00 expecting POAI to rise to within 12 months (a possible 1123.99% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Predictive Oncology (NASDAQ: POAI) is $0.4085 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Predictive Oncology.
Predictive Oncology’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Predictive Oncology.
Predictive Oncology is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.